Zevra Therapeutics, Inc. (ZVRA)
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohns disease at two years
ADC Therapeutics to Present at November Investor Conferences
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
Incyte annonce de nouveaux résultats issus de l’essai de phase 3b TRuE-AD4 sur Opzelura® (crème à base de ruxolitinib) chez des adultes atteints de dermatite atopique modérée
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
Immatics Appoints Amie Krause as Chief People Officer
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting